Innovative Medicines Initiative

A new analysis says EU’s €3.3B pre-competitive drug research programme is delivering highly-rated science, levering in private money and creating new partnerships. But the full socio-economic benefits are yet to come

An analysis of journal papers indicates IMI’s research has a high impact, but the partnership’s former head Michel Goldman says bibliometrics do not properly reflect the interests of participants. New metrics are needed to assess interdisciplinary projects

The current head of Genome Canada will take over as executive director of the world’s largest pharmaceuticals public-private partnership in September

Europe’s €3B Innovation Medicines Initiative faced scrutiny over pharma companies’ contributions to the programme in the European Parliament this week – and passed the test.

While it has a high reputation for the quality of its basic medical research, Poland lacks the means to translate this into the clinic. International collaboration is needed to help build this infrastructure

Five year programme to develop improved tests for evaluating vaccines

The League of European Research Universities has once again hit out at IP rules and funding levels in the EU’s Innovative Medicines Initiative, saying academics will be discouraged from taking part in the €2B collaborative research programme

The Innovative Medicines Initiative has set out guidelines on how collaborative partners should approach the thorny issue of IP rights, in time for its fourth call

As the second tranche of projects in the €2 billion Innovative Medicines Initiative was announced this week, a quick stock take of progress to date hints at what this wide-ranging collaboration could deliver

The Innovative Medicines Initiative gets under way in earnest on 30 April when would-be participants will learn about the scope of the programme.